WT-gag-TCR modified T cells

WT-gag-TCR modified T cells are autologous CD8+ T lymphocytes that have been genetically engineered to express a wild-type (natural affinity) T cell receptor (TCR) specific for the HIV-1 gag epitope SL9 (SLYNVATL), which is presented by HLA-A*02. These engineered cells are produced by isolating a patient's own T cells and transducing them with lentiviral vectors encoding the wild-type gag-specific TCR. The primary mechanism of action is to redirect the specificity of patient-derived cytotoxic (CD8+) T lymphocytes toward HIV-infected cells expressing the SL9 epitope, thereby enhancing immune-mediated clearance of infected targets. This approach is being investigated as an adoptive cellular immunotherapy for HIV infection in patients who are well-controlled on antiretroviral therapy[3]. The development and initial clinical evaluation were conducted at the University of Pennsylvania in collaboration with Adaptimmune.

Other names

wild-type gag-specific TCR modified T cellswild-type GAG-TCR modified T cells